Letter by Hjemdahl et al regarding article, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial". - Suppr | 超能文献

Letter by Hjemdahl et al regarding article, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial".

作者信息

Hjemdahl Paul, Johnsson Hans, Wallén N Håkan

出版信息

Circulation. 2013 Mar 19;127(11):e505. doi: 10.1161/CIRCULATIONAHA.112.135343.

DOI:10.1161/CIRCULATIONAHA.112.135343

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Letter by Hjemdahl et al regarding article, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial".

Circulation. 2013 Mar 19;127(11):e505. doi: 10.1161/CIRCULATIONAHA.112.135343.

2

Letter by David et al regarding article, "Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) Randomized Trial".

Circulation. 2013 Mar 19;127(11):e504. doi: 10.1161/CIRCULATIONAHA.112.133041.

3

Response to letters regarding article, “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”.

Circulation. 2013 Mar 19;127(11):e506. doi: 10.1161/circulationaha.112.154732.

4

Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.

Circulation. 2012 Jul 17;126(3):343-8. doi: 10.1161/CIRCULATIONAHA.111.090464. Epub 2012 Jun 14.

5

Letter by Reynolds et al regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial".

Circulation. 2012 Jan 24;125(3):e291; author reply e293-4. doi: 10.1161/CIRCULATIONAHA.111.056077.

6

Letter by Govindarajan and Salgado regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial".

Circulation. 2012 Jan 24;125(3):e290; author reply e293-4. doi: 10.1161/CIRCULATIONAHA.111.053710.

7

Letter by Reiffel regarding article, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial".

Circulation. 2012 Jan 24;125(3):e292; author reply e293-4. doi: 10.1161/CIRCULATIONAHA.111.057422.

8

Anticoagulation, novel agents, and procedures: can we pardon the interruption?

Circulation. 2012 Jul 17;126(3):255-7. doi: 10.1161/CIRCULATIONAHA.112.115188. Epub 2012 Jun 14.

9

Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.

Circulation. 2011 May 31;123(21):2363-72. doi: 10.1161/CIRCULATIONAHA.110.004747. Epub 2011 May 16.

10

Letter by Stollberger and Finsterer regarding article, "intracranial hemorrhage in patients with atrial fibrillation during anticoagulation with Warfarin or Dabigatran: the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial".

Stroke. 2012 Sep;43(9):e93. doi: 10.1161/STROKEAHA.112.661918. Epub 2012 Jul 3.